Literature DB >> 1433529

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

M K Gorny1, A J Conley, S Karwowska, A Buchbinder, J Y Xu, E A Emini, S Koenig, S Zolla-Pazner.   

Abstract

The third variable region (V3) of the HIV-1 gp120 envelope glycoprotein is thought to induce potent neutralizing antibodies which are generally defined as type specific and reactive with individual viral isolates. In contrast, the CD4-binding domain is thought to induce neutralizing antibodies that are group specific and capable of neutralizing all isolates of HIV-1. However, in this study, we used a panel of human monoclonal antibodies to these regions of gp120 which displays specificities and neutralizing activities that challenge these tenets. In particular, we used a human monoclonal antibody to the V3 domain with exceptionally potent and broad neutralizing activity against many diverse HIV-1 isolates. The anti-CD4-binding domain antibodies, on the other hand, showed a more restricted pattern of activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1433529      PMCID: PMC240465     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

2.  Topographical and functional mapping of epitopes on hog cholera virus with monoclonal antibodies.

Authors:  G Wensvoort
Journal:  J Gen Virol       Date:  1989-11       Impact factor: 3.891

3.  Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines.

Authors:  J E Robinson; D Holton; S Pacheco-Morell; J Liu; H McMurdo
Journal:  AIDS Res Hum Retroviruses       Date:  1990-05       Impact factor: 2.205

4.  Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.

Authors:  B H Hahn; G M Shaw; M E Taylor; R R Redfield; P D Markham; S Z Salahuddin; F Wong-Staal; R C Gallo; E S Parks; W P Parks
Journal:  Science       Date:  1986-06-20       Impact factor: 47.728

5.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14.

Authors:  B Sherry; A G Mosser; R J Colonno; R R Rueckert
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

7.  Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition.

Authors:  J Goudsmit; C A Boucher; R H Meloen; L G Epstein; L Smit; L van der Hoek; M Bakker
Journal:  AIDS       Date:  1988-06       Impact factor: 4.177

8.  Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees.

Authors:  E A Emini; P L Nara; W A Schleif; J A Lewis; J P Davide; D R Lee; J Kessler; S Conley; S Matsushita; S D Putney
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  178 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

6.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

7.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

9.  Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Authors:  Mei-Yun Zhang; Vidita Choudhry; Igor A Sidorov; Vladimir Tenev; Bang K Vu; Anil Choudhary; Hong Lu; Gabriela M Stiegler; Hermann W D Katinger; Shibo Jiang; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Immunol Methods       Date:  2006-10-16       Impact factor: 2.303

10.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.